In children with autism, lower levels of two immune signaling proteins—CXCL1 and RANTES—after an anti-inflammatory diet are linked to better word-finding skills and improved attention, indicating these proteins may be key biological links between diet and cognitive improvement.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether reductions in CXCL1 and RANTES consistently correlate with improvements in verbal fluency and attention across multiple dietary intervention studies in children with ASD.
A systematic review and meta-analysis of at least five RCTs measuring pre-post CXCL1, RANTES, and standardized verbal fluency (semantic/phonemic) and attention (CPT, Digit Span) outcomes in children with ASD, using consistent assays and cognitive batteries, adjusting for baseline levels and diet adherence.
Whether selectively reducing CXCL1 or RANTES (via targeted immunomodulation) improves verbal fluency or attention in children with ASD, independent of other dietary effects.
A double-blind RCT with 120 children with ASD, randomized to either a CXCL1-inhibiting biologic (e.g., anti-CXCL1 antibody) or RANTES-inhibiting agent (e.g., CCR5 antagonist) vs. placebo, with pre-post measurement of verbal fluency (semantic fluency test) and attention (CPT-II) as primary outcomes, controlling for diet and medication.
Whether baseline CXCL1 and RANTES levels predict future changes in verbal fluency and attention in children with ASD over time, independent of dietary intervention.
A prospective cohort study following 180 children with ASD for 18 months, measuring plasma CXCL1 and RANTES quarterly and assessing verbal fluency and attention every 6 months without dietary intervention, adjusting for age, sex, and comorbidities.
Whether children with ASD and low verbal fluency have higher baseline CXCL1 levels than those with typical fluency, matched for age and cognitive ability.
A case-control study comparing 50 children with ASD and low verbal fluency (≤1 SD below mean) to 50 matched controls (≥1 SD above mean), measuring baseline plasma CXCL1 and RANTES, controlling for age, sex, IQ, and medication use.
Whether plasma CXCL1 and RANTES levels are inversely correlated with verbal fluency and attention scores in children with ASD at a single time point.
A cross-sectional analysis of 250 children with ASD, measuring plasma CXCL1 and RANTES and administering standardized verbal fluency and attention tests (e.g., Animal Naming, CPT-II) at one visit, adjusting for age, sex, and BMI.